Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies

被引：21

作者：

Giovannoni, G ^{[1
]}

机构：

[1] UCL, Inst Neurol, Dept Neuroinflammat, London WC1N 3BG, England

来源：

NEUROLOGY | 2003年 / 61卷 / 09期

关键词：

D O I：

10.1212/01.WNL.0000092379.75791.5D

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Up to 35% of people with multiple sclerosis (MS) treated with interferon-beta (IFNbeta) develop neutralizing anti-IFNbeta antibodies within 2 years of starting therapy. These antibodies reduce or abolish the biologic effects and clinical efficacy of IFNbeta. The overall efficacy of IFNbeta and hence the cost-effectiveness of this treatment would be substantially improved if the development of neutralizing antibodies (NAbs) could be prevented or reversed. Strategies used to prevent or reverse the development of NAbs with other biologic compounds, including improvements in the manufacturing process, immunosuppression, induction of tolerance, and deimmunization, will be reviewed.

引用

页码：S13 / S17

页数：5

共 30 条

[11]

Duquette P, 1996, NEUROLOGY, V47, P889

[12] Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) [J].

Durelli, L ;

Verdun, E ;

Barbero, P ;

Bergui, M ;

Versino, E ;

Ghezzi, A ;

Montanari, E ;

Zaffaroni, M .

LANCET, 2002, 359 (9316) :1453-1460

[13] Pure red-cell aplasia due to anti-erythropoietin antibodies [J].

Eckardt, KU ;

Casadevall, N .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (05) :865-869

[14] Neutralising antibodies to interferon beta during the treatment of multiple sclerosis [J].

Giovannoni, G ;

Munschauer, FE ;

Deisenhammer, F .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (05) :465-469

[15] The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO) [J].

Hay, CRM ;

Baglin, TP ;

Collins, PW ;

Hill, FGH ;

Keeling, DM .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) :78-90

[16] Regulation of receptor activator of NF-κB ligand-induced osteoclastogenesis by endogenous interferon-β (INF-β) and suppressors of cytokine signaling (SOCS) -: The possible counteracting role of SOCSs in IFN-β-inhibited osteoclast formation [J].

Hayashi, T ;

Kaneda, T ;

Toyama, Y ;

Kumegawa, M ;

Hakeda, Y .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (31) :27880-27886

[17]

HERNDON RM, 1999, INT J MS CARE, V2, P1

[18]

Hochuli E, 1997, J INTERF CYTOK RES, V17, pS15

[19]

Ingerslev J., 2000, Haematologica, V85, P15

[20] Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. [J].

Jacobs, LD ;

Beck, RW ;

Simon, JH ;

Kinkel, RP ;

Brownscheidle, CM ;

Murray, TJ ;

Simonian, NA ;

Slasor, PJ ;

Sandrock, AW .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13) :898-904

← 1 2 3 →